Kodiak Sciences more than doubled on Monday after its Phase 3 DAYBREAK trial showed two experimental wet macular degeneration drugs were non-inferior to Regeneron’s Eylea, adding over $3 billion of market value in a session, BioPharma Dive reported. Ocular Therapeutix, whose own long-acting implant was pitched on the same promise of fewer injections, fell 21% to $7.66. Regeneron traded lower. The read across the sector was simple: Eylea has a six-month rival.
The trial does not quite say that. The Eylea arm, as BioSpace spelled out, was dosed every eight weeks after loading, the original 2 mg label. Regeneron’s own growth product is Eylea HD, dosed every 16 to 20 weeks, and Roche’s Vabysmo reaches 16. Neither was in the study. Zenkuda beat the regimen the market is already walking away from.
The numbers deserve the same care. Zenkuda patients gained 7.2 letters of vision on average at one year against 7.6 on Eylea, a gap the non-inferiority design was built to tolerate, with a p-value of 0.0007 on that test. Tabirafusp-ted gained 6.3 letters. On durability, 54% of Zenkuda patients were on six-month dosing at year one under a strict “any fluid, treat” retreatment rule. That is a genuine result. It also means 46% were not, and the headline number is a share of the arm rather than its typical patient.
Safety is where Kodiak has the cleanest story. The company reported zero cases of intraocular inflammation on Zenkuda and 0.4% on tabirafusp-ted, and adverse events broadly tracked Eylea. For a retina drug, inflammation is the line physicians read first, and it has sunk long-acting candidates before.
The Molecule Failed Once Already
Zenkuda is tarcocimab tedromer, the same drug that failed to match Eylea in an earlier trial roughly four years ago and took most of Kodiak’s valuation with it. Fierce Biotech called Monday’s result a resurrection, and the word fits. What changed was the protocol more than the chemistry: the redesigned study used fluid detection to set each patient’s interval. That is a meaningful finding about how to use the drug. It is also a reminder that the win belongs partly to the dosing algorithm, which a competitor can study too.
Our view: the data are good enough to file, and Kodiak says it will submit a Biologics License Application in the fourth quarter covering wet AMD, diabetic retinopathy and retinal vein occlusion. They are not good enough to price as if Eylea HD has been beaten, because nobody has run that trial. Kodiak argues newer rivals underdeliver on durability in real-world use, and it may be right, but that is an argument from outside its own study. Payers will ask for the head-to-head. Kodiak should run it against Eylea HD before launch rather than after, and investors who added $3 billion in a day should wait for it before treating Regeneron’s franchise as the one under threat.
Ocular’s 21% drop is the more defensible move of Monday’s two. A six-month injection with a clean safety record makes an implant’s convenience case harder, whatever it does to Eylea.